Cargando…
Synergistic FRET assays for drug discovery targeting RyR2 channels
A key therapeutic target for heart failure and arrhythmia is the deleterious leak through sarcoplasmic reticulum (SR) ryanodine receptor 2 (RyR2) calcium release channels. We have previously developed methods to detect the pathologically leaky state of RyR2 in adult cardiomyocytes by monitoring RyR2...
Autores principales: | Rebbeck, RobynT., Ginsburg, Kenneth S., Ko, Christopher Y., Fasoli, Anna, Rusch, Katherine, Cai, George F., Dong, Xiaoqiong, Thomas, David D., Bers, Donald M., Cornea, Razvan L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088286/ https://www.ncbi.nlm.nih.gov/pubmed/35405106 http://dx.doi.org/10.1016/j.yjmcc.2022.04.002 |
Ejemplares similares
-
RyR1-targeted drug discovery pipeline integrating FRET-based high-throughput screening and human myofiber dynamic Ca(2+) assays
por: Rebbeck, Robyn T., et al.
Publicado: (2020) -
Simvastatin activates single skeletal RyR1 channels but exerts more complex regulation of the cardiac RyR2 isoform
por: Venturi, Elisa, et al.
Publicado: (2018) -
Molecular Mechanism of a FRET Biosensor for the Cardiac Ryanodine Receptor Pathologically Leaky State
por: Svensson, Bengt, et al.
Publicado: (2023) -
Molecular Mechanism of a FRET Biosensor for the Cardiac Ryanodine Receptor Pathologically Leaky State
por: Svensson, Bengt, et al.
Publicado: (2023) -
How does flecainide impact RyR2 channel function?
por: Salvage, Samantha C., et al.
Publicado: (2022)